Crossref
Semaglutide: FDA publishes warning amid reports of patients overdosing
BMJ · 2024
DOI: 10.1136/bmj.q1696 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ, 2024. Verfasst von Elisabeth Mahase. Beteiligte Einrichtung: The BMJ. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, United States Food and Drug Administration, Hypoglycemic Agents. Die Arbeit nennt 1 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Glucagon-Like PeptidesUnited States Food and Drug AdministrationHypoglycemic AgentsHumansUnited StatesDiabetes Mellitus, Type 2Medical OveruseSemaglutide
Substanzen
Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide
Autor:innen und Institutionen
- The BMJ.
Zitieren
APA
Mahase, E. (2024). Semaglutide: FDA publishes warning amid reports of patients overdosing. BMJ. https://doi.org/10.1136/bmj.q1696
Vancouver
Mahase E. Semaglutide: FDA publishes warning amid reports of patients overdosing. BMJ. 2024. doi:10.1136/bmj.q1696
BibTeX
@article{Mahase2024,
author = {Mahase, Elisabeth},
title = {Semaglutide: FDA publishes warning amid reports of patients overdosing},
journal = {BMJ},
year = {2024},
doi = {10.1136/bmj.q1696}
}
EUVIMED